Cathepsin S inhibition as a treatment for lung inflammation and lung damage in Chronic Lung Disease

点击翻译按钮获取中文摘要

The cells lining the upper part of the respiratory tract, called bronchial epithelial cells, play an important role in defending the lung against any foreign particles landing on this surface including bacteria, viruses and smoke particles. However, over time, particularly in individuals who have smoked cigarettes for a long period of their life, constant exposure of bronchial epithelial cells to the particles in cigarette smoke can alter the function of these cells. The cells can start dying more rapidly and can also produce chemicals called cytokines that can cause tissue damage to the airways, a process called inflammation. This can lead to a condition called chronic obstructive pulmonary disease (COPD) which is thought to affect many people worldwide (including the UK) and is now the 3rd leading cause of death worldwide. We have found a way to reduce cells from dying and producing cytokines by inhibiting a protein produced by epithelial cells called cathepsin S (CTSS). The identification of CTSS in this role has been uncovered by the use of specific inhibitors of CTSS. We now wish to learn more about how CTSS can make the lung more inflammatory and lead to increased cell death by looking at the activation of another group of proteins called protease activated receptors (PARs) and chemokines which are known to be activated by CTSS and can increase inflammation. We will also test how well these CTSS inhibitors work in a mouse model of COPD. If we see improvements in mouse lung function, reduced inflammation and a reduction in lung damage in this model this will bode well for taking these CTSS inhibitors forward into future clinical trials in individuals with COPD. The very clear application of this study is in the targeting of CTSS to improve bronchial cell function and reduce the progression of COPD, although there is a potential role for this CTSS-mediated pathway in other disease processes including gastrointestinal and dermatological disorders. In future studies, we will test CTSS inhibitors in clinical trials for COPD, which is a very real possibility as we are set-up in Queen's to carry out such studies in Queen's Belfast as part of the NIHR Respiratory Translational Research Collaboration group.